Teva Announces Launch of a Generic Version of Ranexa (ranolazine) Extended-Release Tablets in the United States

Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Ranexa (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S.

Ranolazine Extended-Release Tablets are indicated for the treatment of chronic angina.

“We’re pleased to add to our portfolio of generic medicines that offer another treatment option for people living with chronic conditions like angina,” said Brendan O’Grady, EVP and Head of North America Commercial.

With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Ranolazine Extended-Release Tablets has annual sales of nearly $938 million in the U.S., according to IQVIA data as of February 2019.